Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab in Patients With Advanced Gastric Cancer

NCT03609359 is registered in ClinicalTrials.gov with National Cancer Center Hospital East as lead sponsor.

NCT NCT03609359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03609359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab in Patients With Advanced Gastric Cancer
Lead sponsor
National Cancer Center Hospital East
Phase
Phase 2
Overall status
Completed
Start date
October 3, 2018
Completion date
April 30, 2021
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric cancer